Liver transplantation for hepatitis B liver disease and concomitant hepatocellular carcinoma in the United States With hepatitis B immunoglobulin and nucleoside/nucleotide analogues
Jeffrey Campsen, Michael Zimmerman, James Trotter, Johnny Hong, Chris Freise, Robert Brown, Andrew Cameron, Mark Ghobrial, Igal Kam, Ronald Busuttil, Sammy Saab, Curtis Holt, Jean Emond, Jessica Stiles, Thresiamma Lukose, Matthew Chang, Goran Klintmalm – 15 July 2013 – Reinfection with hepatitis B virus (HBV) after liver transplantation (LT) may favor the recurrence of hepatocellular carcinoma (HCC), and combination therapy with hepatitis B immunoglobulin (HBIG) and nucleoside/nucleotide analogues may reduce HBV recurrence after LT.